Item Posts Archive - Page 36 of 1770 - Medivizor
Navigation Menu

Evaluating treosulfan vs reduced-intensity busulfan conditioning for allogeneic hematopoietic cell transplantation in older patients with acute myeloid leukemia

Evaluating treosulfan vs reduced-intensity busulfan conditioning for allogeneic hematopoietic cell transplantation in older patients with acute myeloid leukemia

Posted by on Dec 31, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to compare the outcomes of allogeneic hematopoietic cell transplant (alloHCT) for older patients with acute myeloid leukemia (AML) using treosulfan (Trecondi) compared to reduced intensity busulfan (Myleran) conditioning.  This study concluded that treosulfan conditioning appears to be more suitable for...

Read More

How effective and safe is rituximab biosimilar HLX01 in patients with moderate to severe rheumatoid arthritis?

How effective and safe is rituximab biosimilar HLX01 in patients with moderate to severe rheumatoid arthritis?

Posted by on Dec 31, 2022 in Rheumatoid Arthritis | 0 comments

In a nutshell This study evaluated the effectiveness and safety of rituximab (Rituxan) biosimilar HLX01 combined with methotrexate (MTX; Trexall) in patients with moderate to severe rheumatoid arthritis (RA) following inadequate responses to MTX. The study showed that HLX01 added to MTX resulted in improvements compared to placebo in these...

Read More

How beneficial is the addition of metformin to insulin therapy for adolescents with type 1 diabetes?

How beneficial is the addition of metformin to insulin therapy for adolescents with type 1 diabetes?

Posted by on Dec 31, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study assessed the effectiveness and safety of adding metformin (Glucophage) to insulin therapy in the treatment of adolescents with type 1 diabetes (T1D). The study showed that the use of metformin in these patients resulted in improved blood glucose control and body mass index (BMI) with an increased risk of...

Read More

Is the use of sodium-glucose cotransporter 2 inhibitors related to the occurrence of eye diseases in patients with type 2 diabetes?

Is the use of sodium-glucose cotransporter 2 inhibitors related to the occurrence of eye diseases in patients with type 2 diabetes?

Posted by on Dec 31, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study investigated the link between sodium-glucose cotransporter 2 inhibitors (SGLT2is) and eye (ocular) diseases in patients with type 2 diabetes (T2D). The data showed that there was no link between the occurrence of eye diseases and SGLT2is in these patients. Some SGLT2is such as ertugliflozin (Steglatro) and empagliflozin...

Read More

Evaluating the long-term outcomes of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutated advanced melanoma.

Evaluating the long-term outcomes of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutated advanced melanoma.

Posted by on Dec 31, 2022 in Melanoma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of encorafenib (Braftovi) alone or in combination with binimetinib (Mektovi) or vemurafenib (Zelboraf) alone in patients with BRAF-mutated advanced melanoma. The data showed that the encorafenib plus binimetinib combination lead to long-term effectiveness and no new safety...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor